Publications in collaboration with researchers from Pfizer (United States) (16)

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2013

  1. A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs

    Annals of Clinical Psychiatry, Vol. 25, Núm. 1, pp. 17-26

2012

  1. Pregabalin for the discontinuation of long-term benzodiazepines use: An assessment of its effectiveness in daily clinical practice

    European Psychiatry, Vol. 27, Núm. 4, pp. 301-307

2011

  1. Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: Is there still room for improvement?

    Annals of General Psychiatry, Vol. 10

  2. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use

    European Addiction Research, Vol. 17, Núm. 5, pp. 262-270

  3. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study

    European Neuropsychopharmacology, Vol. 21, Núm. 12, pp. 867-875

2010

  1. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort

    Schizophrenia Research, Vol. 119, Núm. 1-3, pp. 101-109

  2. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study

    Journal of Clinical Psychiatry, Vol. 71, Núm. 3, pp. 280-286

2009

  1. Prevalencia clinica y motivo de consulta en pacientes con trastorno de ansiedad generalizada atendidos en consultas ambulatorias de psiquiatria en España. Resultados del estudio LIGANDO

    Actas Espanolas de Psiquiatria, Vol. 37, Núm. 1, pp. 17-20

2008

  1. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study

    Schizophrenia Research, Vol. 104, Núm. 1-3, pp. 1-12

  2. Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study

    Schizophrenia Research, Vol. 99, Núm. 1-3, pp. 23-28

2007

  1. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study

    Schizophrenia Research, Vol. 90, Núm. 1-3, pp. 162-173

2004

  1. Economic consequences of the adverse reactions related with antipsychotics: An economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 28, Núm. 8, pp. 1287-1297

2003

  1. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the eire study

    Journal of Sex and Marital Therapy, Vol. 29, Núm. 2, pp. 125-147

  2. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: Results of the EIRE study

    Schizophrenia Research, Vol. 62, Núm. 1-2, pp. 77-88

2002

  1. Frequency of extrapyramidal adverse reactions in schizophrenic outpatients treated with risperidone, olanzapine, quetiapine or haloperidol: Results of the EIRE study

    Clinical Drug Investigation, Vol. 22, Núm. 9, pp. 609-622